YGYihui Gu

Yihui Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yihui Gu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Qingfeng Li

    Department of Plastic & Reconstructive Surgery Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    7 shared publications
  • Chengjiang Wei

    Neurofibromatosis Type 1 Center and Laboratory for Neurofibromatosis Type 1 Research Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    6 shared publications
  • Zhichao Wang

    Department of Plastic and Reconstructive Surgery , Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200011 , China

    6 shared publications
  • Jingxuan Huang

    Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

    4 shared publications
  • Jun Liu

    Shanghai Ninth People’s Hospital 1 Department of Plastic and Reconstructive Surgery Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Yuehua Li

    Shanghai Ninth People’s Hospital 1 Department of Plastic and Reconstructive Surgery Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications

Latest Publications

  • Open Access

    Data from Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

    by Zhichao Wang, Jingxuan Huang, Jun Liu, Yuehua Li, Chengjiang Wei, Yihui Gu, Ying Cheng, Yanjun Xu, Hongqi Tian, Qingfeng Li

    Purpose:Plexiform neurofibromas (PN) present a significant clinical challenge, with a notable unmet need for effective and well-tolerated therapies, particularly for the adult population.Patients and Methods:A single-arm, open-label, phase IIa trial of tunlametinib was conducted to assess its efficacy and safety in adults with inoperable, radiologically measurable PN. Patients received tunlametinib at a dose of 9 mg twice daily, following a continuous 21-day cycle regimen. The primary endpoint was the confirmed objective response rate (ORR), and secondary endpoints included disease control rate, duration of response, progression-free survival, and improvements in patient-reported outcomes (PRO) compared with baseline. Exploratory analyses integrating clinical variables and single-cell transcriptomic profiles were performed to explore response heterogeneity.Results:Of 15 adults (10 males and five females; median age, 27 years; range, 18–45), eight patients achieved a confirmed partial response, with an ORR of 53.3% (95% confidence interval, 26.69–78.73) and a median neurofibroma volume reduction of −23.5% (range, 1.6% to −49.1%). Significant improvements in multiple PRO domains were observed, including Patients’ Global Impression of Change and the Plexiform Neurofibromas Quality of Life scale. Regarding safety, all patients experienced at least one treatment-related adverse event, the majority of which were grade 1 or 2. Single-cell RNA sequencing profiling of pretreatment biopsies from one rapid responder and two gradual responders revealed substantial microenvironmental heterogeneity.Conclusions:Tunlametinib demonstrated promising efficacy and an acceptable safety profile in adults with PN, broadly aligning with the prior PN trials, including selumetinib and mirdametinib.

  • Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

    by Zhichao Wang, Jingxuan Huang, Jun Liu, Yuehua Li, Chengjiang Wei, Yihui Gu, Ying Cheng, Yanjun Xu, Hongqi Tian, Qingfeng Li

    Purpose: Plexiform neurofibromas (PN) present a significant clinical challenge, with a notable unmet need for effective and well-tolerated therapies, particularly for the adult population. Patients and Methods: A single-arm, open-label, phase IIa trial of tunlametinib was conducted to assess its efficacy and safety in adults with inoperable, radiologically measurable PN. Patients received tunlametinib at a dose of 9 mg twice daily, following a continuous 21-day cycle regimen. The primary endpoint was the confirmed objective response rate (ORR), and secondary endpoints included disease control rate, duration of response, progression-free survival, and improvements in patient-reported outcomes (PRO) compared with baseline. Exploratory analyses integrating clinical variables and single-cell transcriptomic profiles were performed to explore response heterogeneity. Results: Of 15 adults (10 males and five females; median age, 27 years; range, 18–45), eight patients achieved a confirmed partial response, with an ORR of 53.3% (95% confidence interval, 26.69–78.73) and a median neurofibroma volume reduction of −23.5% (range, 1.6% to −49.1%). Significant improvements in multiple PRO domains were observed, including Patients’ Global Impression of Change and the Plexiform Neurofibromas Quality of Life scale. Regarding safety, all patients experienced at least one treatment-related adverse event, the majority of which were grade 1 or 2. Single-cell RNA sequencing profiling of pretreatment biopsies from one rapid responder and two gradual responders revealed substantial microenvironmental heterogeneity. Conclusions: Tunlametinib demonstrated promising efficacy and an acceptable safety profile in adults with PN, broadly aligning with the prior PN trials, including selumetinib and mirdametinib.


  • Unraveling intratumoral complexity in metastatic dermatofibrosarcoma protuberans through single-cell RNA sequencing analysis

    by Ling-Ling Ge, Zhi-Chao Wang, Cheng-Jiang Wei, Jing-Xuan Huang, Jun Liu, Yi-Hui Gu, Wei Wang, Qing-Feng Li

    Dermatofibrosarcoma protuberans (DFSP) stands as a rare and locally aggressive soft tissue tumor, characterized by intricated molecular alterations. The imperative to unravel the complexities of intratumor heterogeneity underscores effective clinical management. Herein, we harnessed single-cell RNA sequencing (scRNA-seq) to conduct a comprehensive analysis encompassing samples from primary sites, satellite foci, and lymph node metastases. Rigorous preprocessing of raw scRNA-seq data ensued, and employing t-distributed stochastic neighbor embedding (tSNE) analysis, we unveiled seven major cell populations and fifteen distinct subpopulations. Malignant cell subpopulations were delineated using infercnv for copy number variation calculations. Functional and metabolic variations of diverse malignant cell populations across samples were deciphered utilizing GSVA and the scMetabolism R packages. Additionally, the exploration of differentiation trajectories within diverse fibroblast subpopulations was orchestrated through pseudotime trajectory analyses employing CytoTRACE and Monocle2, and further bolstered by GO analyses to elucidate the functional disparities across distinct differentiation states. In parallel, we segmented the cellular components of the immune microenvironment and verified the presence of SPP1+ macrophage, which constituted the major constituent in lymph node metastases. Remarkably, the CellChat facilitated a comprehensive intercellular communication analysis. This study culminates in an all-encompassing single-cell transcriptome atlas, propounding novel insights into the multifaceted nature of intratumor heterogeneity and fundamental molecular mechanisms propelling metastatic DFSP.


  • Open Access

    Knockdown of NCOR2 Inhibits Cell Proliferation via BDNF/TrkB/ERK in NF1-Derived MPNSTs

    by Yuehua Li, Manhon Chung, Rehanguli Aimaier, Chengjiang Wei, Wei Wang, Lingling Ge, Beiyao Zhu, Zizhen Guo, Mingyang Wang, Yihui Gu, et al.

    (1) Background: malignant peripheral nerve sheath tumours (MPNSTs) are aggressive Schwann cell-derived sarcomas with dismal prognoses. Previous studies have shown that nuclear receptor corepressor 2 (NCOR2) plays a vital role in neurodevelopment and in various tumours. However, the impact of NCOR2 on the progression of MPNST remains unclear. (2) Methods: by GEO database, MPNST tissue microarray, and NF1-related tumour tissues and cell lines were used to explore NCOR2 expression level in the MPNSTs. The role and mechanism of NCOR2 in NF1-derived MPNSTs were explored by experiments in vivo and in vitro and by transcriptome high-throughput sequencing. (3) Results: NCOR2 expression is significantly elevated in NF1-derived MPNSTs and is associated with patient 10-year survival time. Knockdown of NCOR2 suppressed NF1-derived MPNST cell proliferation by blocking the cell cycle in the G0/G1 phase. Moreover, decreased NCOR2 expression could down-regulate MAPK signal activity through the BDNF/TrkB pathway. (4) Conclusions: our findings demonstrated that NCOR2 expression is significantly elevated in NF1-derived MPNSTs. NCOR2 knockdown can inhibit NF1-derived MPNST cell proliferation by weakened BDNF/TrkB/ERK signalling. Targeting NF1-derived MPNSTs with TrkB inhibitors, or in combination with ERK inhibitors, may be a novel therapeutic strategy for clinical trials.


  • Open Access

    Photonic hyperthermia of malignant peripheral nerve sheath tumors at the third near-infrared biowindow

    by Yihui Gu, Zhichao Wang, Chengjiang Wei, Yuehua Li, Wei Feng, Wei Wang, Meiqi Chang, Yu Chen, Qingfeng Li

    Background: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that typically carry a dismal prognosis. Given the insensitivity of these tumors to traditional chemotherapy and the absence of effective targeted drugs, new therapeutic strategies are urgently needed. Photothermal therapy (PTT) including near-infrared laser at the third biowindow (NIR-III) has demonstrated significant potential in cancer theranostics due to its minimally invasive nature and excellent therapeutic outcomes. However, the passive utilization of photothermal agents (PTAs) with poor target specificity and biocompatibility substantially hinders the clinical translation and application of this method.Methods: We evaluated the efficiency, safety, and underlying mechanisms of NIR-III without PTAs in the treatment of MPNSTs. The photothermal performance and tissue penetration capability of the NIR-III laser were evaluated in human MPNST cell lines using CCK-8, Calcein-AM and propidium iodide (PI) staining, and Annexin V-FITC/PI assays. The tumor xenografted mice model was used for evaluating the efficacy and biosafety of NIR-III photothermal ablation. Finally, the underlying mechanisms of NIR-III treatment, explored by whole-transcriptome sequencing, are further verified by RT-qPCR.Results: We found that although the NIR-III photothermal treatment efficiency varied among individuals, which was possibly influenced by different endoplasmic reticulum stress responses, the expected antineoplastic effect was ultimately achieved after adjustment of the power density and radiation duration.Conclusions: The present study provides an intriguing noninvasive therapy for MPNSTs that accelerates the clinical translation of PTT while avoiding the biocompatibility issues arising from PTAs.Funding: This work was supported by grants from National Natural Science Foundation of China (82102344; 82172228); Shanghai Rising Star Program supported by Science and Technology Commission of Shanghai Municipality (20QA1405600); Natural Science Foundation of Shanghai (22ZR1422300); Science and Technology Commission of Shanghai Municipality (19JC1413) ; “Chenguang Program” supported by Shanghai Education Development Foundation (SHEDF) (19CG18); Shanghai Municipal Key Clinical Specialty (shslczdzk00901); Innovative research team of high-level local universities in Shanghai (SSMU-ZDCX20180700).


  • Open Access

    Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal–Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I

    by Wei Wang, Xi-Wei Cui, Yi-Hui Gu, Cheng-Jiang Wei, Yue-Hua Li, Jie-Yi Ren, Man-Hon Chung, Re-Han-Gu-Li Aimaier, Hai-Bing Zhang, Qing-Feng Li, et al.